Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.00 USD
−35.20 M USD
0.00 USD
8.16 M
About Elicio Therapeutics, Inc.
Sector
Industry
CEO
Robert T. Connelly
Website
Headquarters
Boston
Founded
2011
FIGI
BBG00444GM02
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ELTX is 5.08 USD — it has increased by 10.20% in the past 24 hours. Watch Elicio Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Elicio Therapeutics, Inc. stocks are traded under the ticker ELTX.
ELTX stock has risen by 15.45% compared to the previous week, the month change is a 8.55% rise, over the last year Elicio Therapeutics, Inc. has showed a −28.45% decrease.
We've gathered analysts' opinions on Elicio Therapeutics, Inc. future price: according to them, ELTX price has a max estimate of 10.00 USD and a min estimate of 9.00 USD. Watch ELTX chart and read a more detailed Elicio Therapeutics, Inc. stock forecast: see what analysts think of Elicio Therapeutics, Inc. and suggest that you do with its stocks.
ELTX reached its all-time high on Feb 19, 2021 with the price of 263.00 USD, and its all-time low was 2.96 USD and was reached on Feb 7, 2024. View more price dynamics on ELTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ELTX stock is 9.93% volatile and has beta coefficient of 0.89. Track Elicio Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Elicio Therapeutics, Inc. there?
Today Elicio Therapeutics, Inc. has the market capitalization of 54.73 M, it has decreased by −12.97% over the last week.
Yes, you can track Elicio Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Elicio Therapeutics, Inc. is going to release the next earnings report on Nov 11, 2024. Keep track of upcoming events with our Earnings Calendar.
ELTX earnings for the last quarter are −0.64 USD per share, whereas the estimation was −0.96 USD resulting in a 33.33% surprise. The estimated earnings for the next quarter are −0.73 USD per share. See more details about Elicio Therapeutics, Inc. earnings.
Elicio Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ELTX net income for the last quarter is −7.23 M USD, while the quarter before that showed −11.83 M USD of net income which accounts for 38.88% change. Track more Elicio Therapeutics, Inc. financial stats to get the full picture.
No, ELTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 32.00 employees. See our rating of the largest employees — is Elicio Therapeutics, Inc. on this list?
Like other stocks, ELTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Elicio Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Elicio Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Elicio Therapeutics, Inc. stock shows the sell signal. See more of Elicio Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.